Market News AIOpen the app

ALNY stock news · Alnylam Pharmaceuticals

Stories about Alnylam Pharmaceuticals (ALNY) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for ALNY

Follow Alnylam Pharmaceuticals (ALNY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ALNY
Free on the App Store and Google Play, or on the web.
  1. Nov 9, 2026, 3:26 PM ET · Opinion

    Truist Securities changed Alnylam Pharmaceuticals' rating from Buy to Hold and cut its price target.

    Bad for ALNY

    Alnylam was downgraded from Buy to Hold, and Truist cut its share-price target from $315 to $225. This is a negative signal despite Alnylam's $1 billion buyback authorization.

  2. Nov 8, 2026, 9:25 PM ET · Trial

    Alnylam-Licensed Elebsiran Shows Positive Results in Phase 3 ECLIPSE 1 Trial for Hepatitis Delta

    Good or bad for ALNY?